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Background: Ovarian cancer is one of the commonest gynecologic malignancy. It is the most common cause of death due 
to gynecologic tumors, and accounts for 50% of deaths due to all gynecologic cancer types. Objectives: The aim was to 
discuss and assess ovarian cancer in Misan province and to underline its impact for increased awareness and interest in 
screening and early diagnosis by the determination of the prevalence rates among Maysanian women. Methods: The study 
lasted six months. During this period, we obtained a lot of data from records of the Al-Shifaa Oncology Center in Misan 
province, Iraq. Between September 2016 and February 2017, 50 cases of ovarian cancer from 282 gynecologic cancers were 
recorded. Complete history was obtained for every case. Results: The study showed that ovarian cancer constituted 17.73% of 
all types of cancer. It usually occurred in patients aged 60–70 years (30%). Women lived in urban areas 1.5 times more 
frequently than in rural areas. The most common histopathological type of ovarian cancer was ovarian serous carcinoma 
(46%). The most common stages were stage III and IV, accounting for 76%. Conclusion: Ovarian cancer is the third most 
common gynecologic cancer type. It was more common in women aged 60–70 years. Regarding the family history, the results 
were insignificant. The most common histopathological type of ovarian cancer in this study was ovarian serous carcinoma. 
The most common stages of the disease were advanced stages III and IV.
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Wstęp: Rak jajnika jest jednym z najczęstszych nowotworów złośliwych żeńskich narządów płciowych oraz główną przyczyną 
umieralności z powodu tych nowotworów – odpowiada za 50% zgonów wśród chorych z nowotworami kobiecego układu 
płciowego. Cele: Omówienie i ocena występowania raka jajnika w irackiej prowincji Majsan w celu zwiększenia świadomości 
i zainteresowania badaniami przesiewowymi i wczesnym rozpoznaniem choroby poprzez określenie częstości występowania 
omawianego nowotworu wśród kobiet zamieszkujących region Majsan. Metody: Badanie trwało sześć miesięcy. Uzyskano 
liczne dane z Centrum Onkologii Al-Shifaa w prowincji Majsan w Iraku. W okresie od września 2016 do lutego 2017 roku 
odnotowano 50 przypadków raka jajnika wśród ogółem 282 przypadków nowotworów narządów płciowych. Od każdej 
pacjentki zebrano pełny wywiad. Wyniki: Badanie wykazało, że rak jajnika stanowił 17,73% nowotworów. Rozpoznawano 
go zwykle u kobiet w wieku 60–70 lat (30%). Pacjentki częściej (o 1,5 razy) zamieszkiwały rejony wiejskie. Najczęstszym 
typem histopatologicznym był surowiczy rak jajnika (46%). Chorobę zwykle rozpoznawano w stadium III i IV, co stanowiło 
76% przypadków. Wnioski: Rak jajnika to trzeci co do częstości nowotwór żeńskich narządów płciowych. Występował 
częściej u kobiet w wieku 60–70 lat. Wyniki dotyczące wywiadu rodzinnego nie były istotne. Najczęstszy typ histopatologiczny 
stanowił surowiczy rak jajnika. Chorobę rozpoznawano przeważnie w zaawansowanym stadium – III i IV.
Słowa kluczowe: nowotwory złośliwe żeńskich narządów płciowych, rak jajnika, prowincja Majsan, rak surowiczy
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cancer in United Kingdom women(9). Ovarian cancer is 
most commonly diagnosed after menopause, between the 
age of 60 and 64. Ninety per cent of ovarian cancer cases 
are women over the age of 45 and 80% are women over the 
age of 50(8). Ovarian cancer represents approximately 4% of 
cancers diagnosed in women(9). It occurs more commonly 
in developed countries. Ovarian cancer is the most deadly 
gynecologic cancer(10). The overall incidence in Europe 
is approximately 5–15 per 100,000 women(9). In general, 
a family history of ovarian cancer can indicate a predis-
position to developing it. The major genetic risk factor for 
ovarian cancer is a mutation in BRCA1 or BRCA2 DNA 
mismatch repair genes, which is present in 10% of ovar-
ian cancer cases. Generally, 5–10% of ovarian cancer cases 
have a genetic cause. A significant family history of endo-
metrial cancer, colon cancer, or other gastrointestinal can-
cers may indicate the presence of a syndrome known as 
hereditary non-polyposis colorectal cancer (also known as 
Lynch syndrome), which confers a higher risk for devel-
oping a number of cancers, including ovarian cancer(10,11). 
Ovarian cancers are classified according to the micro-
scopic appearance (histology or histopathology)(12). Their 
gross pathology is very similar regardless of histologic 
type: tumors have solid and cystic masses(7,10). Ovarian 
cancer is staged using the FIGO staging system (Tab. 1)(13).
INTRODUCTION
Ovarian cancer is one of the three most common gynecologic malignancy and is the major cause of death from gynecologic cancer. It constitutes 
about 15–20% of genital malignancies. It is more preva-
lent in the United States and Scandinavian countries but 
much less common in Oriental or Latin American and 
Asian countries(1,2). The most common type of ovarian 
cancer, with more than 95% of cases, is ovarian epithelial 
carcinoma. Less common types include germ cell tumors 
and sex cord stromal tumors(3). The diagnosis is confirmed 
through a biopsy of tissue, usually removed during sur-
gery. If detected and treated in an early stage, it may be 
curable. Treatment usually includes some combination of 
surgery, chemotherapy, and radiation therapy(4). The over-
all five-year survival rate in the United States is 45%(5). 
Globally, as of 2010, about 160,000 people died of ovar-
ian cancer, up from 113,000 in 1990(6). As of 2014, more 
than 220,000 diagnoses of epithelial ovarian cancer were 
made yearly(7). In 2010, in the United States, an estimated 
21,880 new cases were diagnosed and 13,850 women died 
of ovarian cancer. In the United Kingdom, as of 2014, 
approximately 7,000–7,100 yearly diagnoses were made 
and 4,200 deaths occurred(7,8). It is the 5th most common 
Stage Description T N M
I Tumor conﬁned to ovaries or fallopian tube(s) T1
IA Tumor limited to one ovary (capsule intact) or fallopian tube; no tumor on ovarian or fallopian tube surface; no malignant cells in the ascites  
or peritoneal washings
T1a
IB Tumor limited to both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface; no malignant cells  
in the ascites or peritoneal washings
T1b
IC Tumor limited to one or both ovaries or fallopian tubes, with any of the following:
•  IC1: Surgical spill intra-operatively
•  IC2: Capsule ruptured before surgery or tumor on ovarian or fallopian tube surface
•  IC3: Malignant cells present in the ascites or peritoneal washings
T1c
II Tumor involves one or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or peritoneal cancer (Tp) T2
IIA Extension and/or implants on the uterus and/or fallopian tubes and/or ovaries T2a
IIB Extension to other pelvic intraperitoneal tissues T2b
III Tumor involves one or both ovaries or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically conﬁrmed spread  
to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes
T3
IIIA Metastasis to the retroperitoneal lymph nodes with or without microscopic peritoneal involvement beyond the pelvis T1,T2,T3aN1
IIIA1 Positive retroperitoneal lymph nodes only (cytologically or histologically proven) T3a/T3aN1
IIIA1 (i) Metastasis ≤10 mm in greatest dimension (note this is tumor dimension and not lymph node dimension) 
IIIA1 (ii) Metastasis >10 mm in greatest dimension
IIIA2 Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes T3a/T3aN1
IIIB Macroscopic peritoneal metastases beyond the pelvic brim ≤2 cm in greatest dimension, with or without metastasis to the retroperitoneal 
lymph nodes
T3b/T3bN1
IIIC Macroscopic peritoneal metastases beyond the pelvic brim >2 cm in greatest dimension, with or without metastases to the retroperitoneal nodes* T3c/T3cN1
IV Distant metastasis excluding peritoneal metastases:
• IVA: Pleural effusion with positive cytology
• IVB: Metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of abdominal cavity)**
Any T, any N, M1
T3c/T3cN1
* Includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ.
** Parenchymal metastases are stage IVB.
Tab. 1. 2014 FIGO ovarian, fallopian tube, and peritoneal cancer staging system and corresponding TNM(13)
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The histologic grade of a tumor measures how abnor-
mal or malignant its cells look under the microscope. 
The four grades indicate the likelihood of the cancer to 
spread and the higher the grade, the more likely it is for 
this to occur.
i.  Grade I  tumors have well differentiated cells (look 
very similar to the normal tissue) and are the ones 
with the best prognosis.
ii.  Grade II tumors are also called moderately well-dif-
ferentiated and they are made up of cells that resemble 
the normal tissue.
iii.  Grade III tumors have the worst prognosis and their 
cells are abnormal, referred to as poorly differen-
tiated.
iv.  Grade IV – metastasis in ovarian cancer is very com-
mon in the abdomen, and occurs via exfoliation, where 
cancer cells burst through the ovarian capsule and are 
able to move freely throughout the peritoneal cavity. 
Cancer cells can also travel through the lymphatic sys-
tem and metastasize to lymph nodes connected to the 
ovaries via blood vessels(10,14).
Chemotherapy with variable protocols is a general stan-
dard of care for ovarian cancer. Chemotherapy is used 
after surgery to treat any residual disease, if appropri-
ate. In some cases, there may be a reason to perform che-
motherapy first, followed by surgery. Chemotherapy is 
curative in approximately 20% of cases; it is more often 
curative with malignant germ cell tumors than epithe-
lial tumors(15). Chemotherapy in ovarian cancer typically 
consists of platins, a group of platinum-based drugs, com-
bined with non-platins. Common therapies can include 
paclitaxel, cisplatin, topotecan, doxorubicin, epirubicin, 
and gemcitabine. Carboplatin is typically given in com-
bination with either paclitaxel or docetaxel; the typi-
cal combination is carboplatin with paclitaxel(7,9,10,13,15). 
Specific follow-up depends on the type and stage of ovar-
ian cancer, the treatment, and the presence of any symp-
toms. Usually, a check-up appointment is made every 2 to 
3 months initially, followed by twice per year for up to 
5 years. For epithelial ovarian cancers, the most common 
follow-up test is CA-125 level(16). Ovarian cancer usually 
has a relatively poor prognosis. However, in some cases, 
its recurrences are chronically treatable(7). Outcomes 
are worse in the developing world. In 2012, ovar-
ian cancer occurred in 239,000 women and resulted in 
152,000 deaths worldwide. This makes it, among women, 
the seventh most common cancer and the eighth most 
common cause of death from cancer(4).
MATERIAL AND METHODS
Study design and setting
The cross sectional study was based on records from the 
Al-Shifaa Oncology Center in Misan province, Iraq, eval-
uated between September 2016 and February 2017.
Participants and data collection
One thousand seven hundred and sixty-four cancerous 
women, who were treated in the Al-Shifaa Oncology Cen-
ter and Misan Radiotherapy Center, were analyzed. Fifty 
cases of ovarian cancer from 282 gynecologic cancers were 
referred for chemotherapy and radiotherapy.
Clinical parameters
Clinical and pathological data were collected and ana-
lyzed. Full past history was taken for every case including 
age, address, occupation, marital status, pregnancy his-
tory, parity, contraceptive history, family history, histopa-
thology and staging of the disease.
Statistical analysis
The statistical analysis was performed using the Chi-
square test. The lowest level of statistically significant dif-
ferences is equal or below 0.05(17).
RESULTS
The overall prevalence of ovarian cancer
Of 1,064 female cancer patients, only 282 women had gyne-
cologic cancer. Cancer affected five reproductive organs: 
cervix, ovary, uterus, vagina, and vulva. The results revealed 
that ovarian cancer constituted 17.73% of gynecologic can-
cer types, which is of statistical significance (p < 0.05) 
(Tab. 2).
Ovarian cancer in relation 
to socio-demographic variables
The study showed that ovarian cancer usually occurred 
in patients aged 60–70 years (30%) while the percentage 
was zero in extreme age groups, namely 1–10 years and 
80–90 years, with statistical significance of p < 0.01. Ovar-
ian cancer patients typically lived in urban areas: 1.5 times 
more frequently than in rural areas, with a significant differ-
ence (p < 0.05). Pregnancy and parity in this study showed 
relative ratios. As for educational level, 60% had low, 
%CasesGynecologic cancer
17.73%50Ovarian 
29.43%83Cervical 
47.52%134Uterine 
3.90%11Vaginal 
1.42%4Vulvar 
100.00%282Total
Tab. 2.  The overall prevalence of ovarian cancer among all 
gynecologic cancer types
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26% intermediate and 14% high education. Ovarian can-
cer was more common among married women: 39 (78%), 
compared with single women: 11 (22%), which is a signifi-
cant difference (p < 0.01). There was a significant difference 
(p < 0.05) between the percentage of ovarian cancer women 
who used and did not use contraception. Also, there was 
a significant difference in the rate of ovarian cancer between 
housewives (86%) and employed women (14%). The family 
history is a risk factor in the predisposition to ovarian can-
cer, but in this study, the results were insignificant because 
most of the women were uncertain about cancer history in 
their families (Tab. 3).
Ovarian cancer in histopathology
The most common histopathological type of ovarian cancer 
in this study was ovarian serous carcinoma: 24 (48%), with 
presence of other types in different proportions (Tab. 4).
Ovarian cancer and staging
The most common stage of the disease was stage IV, found 
in 42% of cases (Tab. 5).
% CasesAge (years)
0%01–10
4%210–20
6%320–30
18%930–40
22%1140–50
16%850–60
30%1560–70
4%270–80
0%080–90
100%50Total
%CasesPlace of residence
38%19Rural
62%31Urban
100%50Total
%CasesPregnancy history
32%16Nulliparous
34%171–5
34%176–10
100%50Total
%CasesEducation level
20%10Illiterate
40%20Primary school
26%13Secondary school
12%6University
2%1Postgraduate
100%50Total
%CasesMarital status
22%11Single
54%27Married
6%3Divorced
18%9Widow
100%50Total
%Cases Contraception
24%12Yes
76%38No
100%50Total
%CasesOccupation 
14%7Government employee
86%43Housewife
100%50Total
%CasesFamily history
18%9Positive
40%20 Negative
42%21Unknown
100%50Total
Tab. 3.  The percentage of ovarian cancer in relation to socio-de-
mographic variables
%CasesHistopathology pattern
48%24Serous
18%9Mucinous
2%1Yolk sac
2%1Lipid cell tumor
2%1Dysgerminoma
2%1Borderline
6%3Atypical epithelial
0%0Brenner
2%1Cystic follicle
2%1Cystic teratoma
2%1Undifferentiated
10%5Metastasis from colon
4%2Metastasis from breast
100%50Total
Tab. 4.  Ovarian cancer percentages and histopathological pat-
tern of cancer
%CasesStage
12%6I
12%6II
34%17III
42%21IV
100%50Total
Tab. 5. Ovarian cancer percentages and stages 
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DISCUSSION
Ovarian cancer is one of the most common gyneco-
logic cancer types and is the third type after uterine and 
cervical cancers. It constituted 17.73% of all gyneco-
logic cancer types. These percentages were obtained due 
to improved ovarian cancer diagnosis, mainly thanks 
to sonography, which is now more widely available 
in Misan province. This result is similar to the results 
in other studies in Egypt and Jordan(18,19). However, it is 
lower than the percentage reported in studies done in 
Iran(20). Other obtained data showed that ovarian cancer 
was most common in women between 60 and 70 years 
of age, with the percentage of 30%, but it was rare in age 
groups 1–10 years and 80–90 years, with the percentage 
of 0%; this result is the same in other countries, such as 
Egypt, Iran, Canada, Japan, Brazil and the USA(18,20,21). 
In the year 2007, the Middle East Cancer Consortium 
(MECC) evaluated the incidence of ovarian cancer in its 
four member countries, namely Egypt, Cyprus, Jordan, 
and USA and compared it to the incidence in the USA 
based on the SEER data base. This study revealed that 
in Cypriots and US SEER data, most patients with ovar-
ian cancer were in the age group from 50 to 69, while in 
Egypt and Jordan, most patients were below the age of 
50 years(20). Ovarian cancer distribution by age in Saudi 
Arabia in 2008 was 32% in patients aged 45–59 years, 
31% in patients aged 60–74 years, and 3.7% in patients 
aged 0–14 years(22), while in the United Kingdom it was 
70.6% in women aged 75–79 years(23).
Regarding the place of residence, the majority of patients 
were from urban areas (about 62%) and fewer patients 
came from rural areas. In Iran, the rates of female repro-
ductive cancers were significantly higher among residents 
of cities than villages(24). Differences in the prevalence of 
risk factors, including reproductive behavior, between the 
two populations may partly explain this diversity. Regard-
ing parity, 32% of women were nulliparous, 34% had 
between 1 and 5 children and 34% had between 6 and 
10 children. The percentage of women that were single 
was 22%, married 54%, divorced 6% and widows 18%. 
Seventy-six per cent of women in this study did not use 
contraception and 24% used contraception. The major-
ity of patients were housewives (about 86%) while the 
remaining women were employed. There was no signif-
icant difference in the relationship between family his-
tory and ovarian cancer due to the low educational level 
of most patients and social phobia. It has been estimated 
that ovarian cancer is familial hereditary in about 5–10% 
of cases. The most important risk factor of ovarian can-
cer is the presence of this disease in first-degree relatives 
(mother, daughter, sister). The risk increases considerably 
with significant family history, meaning two first-degree 
relatives with ovarian cancer. Familial hereditary ovar-
ian cancer falls into three categories: site-specific famil-
ial ovarian cancer, breast-ovarian cancer syndrome, and 
Lynch syndrome type II. The true familial ovarian cancer 
and/or breast cancer develop mainly due to mutation of 
BRCA1 which is located on the long arm of chromosome 
17q21. The mutation of BRCA2 gene (location on chro-
mosome 13q21) is also responsible for ovarian and breast 
cancer syndrome(25).
The most common histopathological type was serous type 
(48%) followed by mucinous type (about 18%), while the 
following types were the least common: yolk sac, dys-
germinoma, lipid cell tumor, borderline, cystic teratoma 
and undifferentiated epithelial cell (about 2%). As in the 
Middle East consortium study, serous carcinomas pre-
dominated, ranging between 27.2% and 49.9%, followed 
by adenocarcinomas in Jordanians (28.7%) and Egyp-
tians (27.2%). The proportion of mucinous carcino-
mas among Egyptians was 16.1% and among Jordanians 
11.7%, whereas the percentages were low in Cypriot reg-
istries (ranging from 6 to 8.7%(19)), Australia (3.4%), and 
Japan (5.4%)(26). In a Turkish study, 69% of ovarian cancers 
were epithelial stromal tumors, 9% were sex-cord stro-
mal tumors, 5% germ cell tumors, and 15% were meta-
static(27). In Iran, serous adenocarcinoma (57.6%) was the 
most common pathology found in patients with epithelial 
ovarian cancer(28). In Alexandria, serous carcinoma con-
stituted 58%, and mucinous carcinoma17.2%(18). The inci-
dence of the serous type in all ovarian cancer cases in 
our study was higher than that of some studies, whereas 
the incidence of the mucinous type was nearly the same, 
and this could be explained by the predominance of the 
molecular phenotype and genotype that expresses the 
serous histology more in our country.
The largest percentage of our patients presented in 
a late stage: stage III was noted in 34% and stage IV in 
42% of patients. For all patients in this study, the typi-
cal presentation was late; stages III and IV were seen in 
76% of the cases. Similar results, with 78% of stage III 
or IV cases, have also been reported(22). Another study 
found that stages III and IV accounted for only 56.2% 
of their cases(21). In Alexandria, typical presentation was 
late; stage III was the initial presentation in 48 patients 
(41.3%) and stage IV in 44 patients (37.9%), which adds 
up to the total of 79.2% of cases(18). Most of the patients in 
Egypt (84.3%) presented with advanced stage III and IV, 
whereas only 15.7% of patients presented with stage I and 
II(28). While in England, the percentage of stage III was 
31.1% and stage IV was 18.1% whereas stage I was noted 
in 30.6% and stage II in 5% of cases(23). In Iran, most 
patients had a stage I (36.7%) or stage II (35%) disease(28). 
This could be explained by low education standards in 
Misan, resulting in late presentation after the disease has 
advanced and low interest in early detection with regu-
lar screening tests, such as ultrasound examination, as 
well as overlooked cancer risk factors, such as obesity, 
immobility and poor diet in this province. Ovarian can-
cer metastasizes early in its development, often before it 
has been diagnosed. More than 60% of women presented 
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with a stage III or stage IV disease, with cancer already 
spreading beyond the ovaries. Complications of ovarian 
cancer can include its spread to other organs, progressive 
function loss of various organs, ascites, and intestinal 
obstructions, which can be fatal. Intestinal obstructions 
in multiple sites are the most common proximate cause of 
death. Intestinal obstruction in ovarian cancer can either 
be a true obstruction, where tumor blocks the intesti-
nal lumen, or a pseudo-obstruction when tumor pre-
vents normal peristalsis. It is disproportionately deadly 
because it lacks any clear early detection or screening, 
meaning that most cases are not diagnosed until they 
have reached advanced stages(11).
CONCLUSION
Ovarian cancer represents the third most common gyne-
cologic cancer type. It was more common in women aged 
60–70 years. It occurred more frequently in women living 
in urban areas than rural areas while housewives devel-
oped it more frequently than employed women. Preg-
nancy and parity in this study showed relative ratios. 
A high percentage of cancer was noted among married 
women. Ovarian cancer was less common in women who 
used contraception compared with those with no his-
tory of contraception. Regarding the family history, the 
results were insignificant. The most common histopath-
ological type of ovarian cancer in this study was ovar-
ian serous carcinoma. The most common stages of the 
disease were stage III and IV (advanced stages). Tumor 
marker tests play important roles in screening and prog-
nosis of cancer.
RECOMMENDATIONS
Increasing awareness of ovarian cancer. Engaging in can-
cer screening tests for pre-detection and early diagnosis. 
Organizing workshops and conferences with a multidis-
ciplinary team of surgeons, gynecologists, pathologists, 
physicians, oncologists and radiotherapists. Conducting 
further studies to investigate other gynecological cancer 
types, other than ovarian cancer.
Limitations of the study
In this study, the collected data reflect the percentage in our province and 
not in all cities in our country.
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